WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases.
作者： Toshiki Masuishi , Takako Eguchi Nakajima , Kentaro Yamazaki , Shuichi Hironaka , Chiho Kudo
关键词:
摘要: Gastric cancer patients with severe peritoneal metastases, defined as massive ascites and/or inadequate oral intake, have been excluded from clinical trials of new treatments due to poor prognosis and tumor-related complications, such ileus. Based on the results JCOG1108/WJOG7312G study, their when treated 5-fluorouracil/l-leucovorin or plus paclitaxel remained extremely in this setting. Retrospective studies shown promising efficacy modified FOLFOX6 (mFOLFOX6) regimen, improved intake. Therefore, we planned a Phase II study mFOLFOX6 gastric metastases (jRCTs041180007). The primary end point is overall survival, an exploratory analysis comparing findings those using Bayes' theorem. Trial registration Identifier: jRCTs041180007 (jRCTs: Japan Registry Clinical Trials).
sci-hub.st 参考文章(11)
Y. Yamada, K. Higuchi, K. Nishikawa, M. Gotoh, N. Fuse, N. Sugimoto, T. Nishina, K. Amagai, K. Chin, Y. Niwa, A. Tsuji, H. Imamura, M. Tsuda, H. Yasui, H. Fujii, K. Yamaguchi, H. Yasui, S. Hironaka, K. Shimada, H. Miwa, C. Hamada, I. Hyodo, Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer Annals of Oncology. ,vol. 26, pp. 141- 148 ,(2015) , 10.1093/ANNONC/MDU472
M.-H. Ryu, E. Baba, K.H. Lee, Y.I. Park, N. Boku, I. Hyodo, B.-H. Nam, T. Esaki, C. Yoo, B.-Y. Ryoo, E.-K. Song, S.-H. Cho, W.K. Kang, S.H. Yang, D.Y. Zang, D.B. Shin, S.R. Park, K. Shinozaki, T. Takano, Y.-K. Kang, Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS) Annals of Oncology. ,vol. 26, pp. 2097- 2101 ,(2015) , 10.1093/ANNONC/MDV316
Hiroki Hara, Shigenori Kadowaki, Masako Asayama, Akira Ooki, Toko Yamada, Takako Yoshii, Kensei Yamaguchi, First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake. International Journal of Clinical Oncology. ,vol. 23, pp. 275- 280 ,(2018) , 10.1007/S10147-017-1198-7
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal, None, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: A Cancer Journal for Clinicians. ,vol. 68, pp. 394- 424 ,(2018) , 10.3322/CAAC.21492
Hiroki Osumi, Daisuke Takahari, Keisho Chin, Mariko Ogura, Takashi Ichimura, Takeru Wakatsuki, Takeshi Suzuki, Yumiko Ota, Izuma Nakayama, Akira Ooki, Mitsukuni Suenaga, Eiji Shinozaki, Kensei Yamaguchi, Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. OncoTargets and Therapy. ,vol. 11, pp. 8301- 8307 ,(2018) , 10.2147/OTT.S184665
N. Boku, M.-H. Ryu, K. Kato, H.C. Chung, K. Minashi, K.-W. Lee, H. Cho, W.K. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, L.-T. Chen, Y.-K. Kang, Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (attraction-4) Annals of Oncology. ,vol. 30, pp. 250- 258 ,(2019) , 10.1093/ANNONC/MDY540
Y. Kang, K. Chin, H. Chung, S. Kadowaki, S. Oh, N. Nakayama, K. Lee, H. Hara, I. Chung, M. Tsuda, S. Park, H. Hosaka, S. Hironaka, Y. Miyata, M. Ryu, M. Takeuchi, H. Baba, I. Hyodo, Y. Bang, N. Boku, A phase III study of TAS-118 plus oxaliplatin versus S-1 plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer (SOLAR study). Annals of Oncology. ,vol. 30, ,(2019) , 10.1093/ANNONC/MDZ183.002
J. Tabernero, E. Van Cutsem, Y. Bang, C. Fuchs, L. Wyrwicz, K. Lee, I. Kudaba, M. Garrido, H. Chung, H. Castro Salguero, W. Mansoor, M. Braghiroli, E. Goekkurt, J. Chao, Z. Wainberg, U. Kher, S. Shah, S. Kang, K. Shitara, Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Annals of Oncology. ,vol. 30, ,(2019) , 10.1093/ANNONC/MDZ183.001
Hiroyuki Arai, Satoru Iwasa, Narikazu Boku, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Keiko Minashi, Shuichi Hironaka, Naoki Fukuda, Daisuke Takahari, Takako Eguchi Nakajima, Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. BMC Cancer. ,vol. 19, pp. 652- 652 ,(2019) , 10.1186/S12885-019-5720-3
FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis. Anticancer Research. ,vol. 37, pp. 7037- 7042 ,(2017) , 10.21873/ANTICANRES.12174